SCHEMBL6930941

SCHEMBL6930941

CC(N(C)C)n1c(N)nc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
HTT P42858 1/20 0.51
NOS2 P35228 1/20 0.49
NOD1 Q9Y239 2/20 0.46
HSD17B10 Q99714 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
TP53 P04637 2/20 0.46
HPGD P15428 2/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 1/20 0.46
ALPG P10696 1/20 0.46
POLB P06746 1/20 0.45
CXCR4 P61073 1/20 0.44
RPS6KB1 P23443 1/20 0.43
GSK3B P49841 1/20 0.43
ROCK1 Q13464 1/20 0.43
TLR8 Q9NR97 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6934110 0.98 CYP1A2 (0.50) CYP1A2CYP2D6HTTNOS2NOD1
SCHEMBL8564481 0.86 CYP1A2 (0.55) CYP1A2CYP2D6HTTNOS2NOD1
SCHEMBL1980314 0.84 HSD17B10 (0.57) CYP1A2CYP2D6HTTNOS2NOD1
SCHEMBL7847984 0.82 NOS2 (0.55) CYP1A2CYP2D6HTTNOS2NOD1
Bromide SCHEMBL1982279 0.82 HSD17B10 (0.56) CYP1A2CYP2D6HTTNOS2NOD1
SCHEMBL8027446 0.78 KDM4E (0.61) CYP1A2HTTHSD17B10KDM4EALDH1A1
SCHEMBL4581653 0.77 NOS2 (0.49) CYP1A2CYP2D6HTTNOS2NOD1
SCHEMBL21310919 0.77 KDM4E (0.57) CYP1A2CYP2D6HTTNOS2NOD1
SCHEMBL4581651 0.77 NOS2 (0.49) CYP1A2CYP2D6HTTNOS2NOD1
Hydrochloric Acid SCHEMBL8025752 0.76 KDM4E (0.59) CYP1A2HTTHSD17B10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6660870-B1 Serotonergic compounds which possess agonist activity at 5-HT2 receptors effectively lower and control normal and elevated IOP and are useful for treating glaucoma ALCON, INC. (CH) 2003-12-09 US disclosed
WO-2001070705-A1 2-ACYLAMINOBENZIMIDAZOLE DERIVATIVES FOR TREATING GLAUCOMA ALCON, INC. (CH) 2001-09-27 WO disclosed